SCM
AXSM icon

SVB Capital Management’s Axsome Therapeutics AXSM Stock Holding History

SVB Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,849
Closed -$4.11M – 7
2025
Q3 		$4.11M Hold
33,849
– – 12.95% 2
2025
Q2 		$3.53M Hold
33,849
– – 5.63% 4
2025
Q1 		$3.95M Hold
33,849
– – 11.64% 3
2024
Q4 		$2.86M Hold
33,849
– – 4.12% 3
2024
Q3 		$3.04M Buy
+33,849
New +$2.95M 2.75% 4

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SVB Capital Management's AXSM Position: Q4 2025 in Review

SVB Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 33,849 shares — an estimated $4.11M sold.

SVB Capital Management first reported a position in AXSM in Q3 2024 and held it in 5 quarters. The position peaked at $4.11M in Q3 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • SVB Capital Management reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SVB Capital Management sold 33,849 Axsome Therapeutics shares in Q4 2025, an estimated $4.11M.
  • SVB Capital Management first reported a position in Axsome Therapeutics in Q3 2024 and held it in 5 quarters.
  • SVB Capital Management's Axsome Therapeutics position peaked at $4.11M in Q3 2025.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on SVB Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.